The thumbs-up was supported by the Phase III IMAgINE 1 trial, which evaluated two different doses of Humira to induce and maintain clinical remission in children with severe active CD. The chronic, debilitating condition of the gastrointestinal tract affects up to 200,000 children worldwide and in addition to symptoms such as abdominal pain, weight loss and diarrhoea, Abbott noted that paediatric